ORGANIZATION
PhRMA Japan Continues Push Against Off-Year Re-Pricing for Innovative Drugs, HTA Use in Reimbursement Decisions in 2020
Japan should limit the scope of its planned “off-year” re-pricing to off-patent drugs and not apply its healthcare technology assessment (HTA) scheme to reimbursement decisions, the Pharmaceutical Research and Manufacturers of America (PhRMA) reiterated on February 19 as it laid…
To read the full story
Related Article
- Janssen’s Chris Hourigan Succeeds Jonsson as PhRMA Japan Chair
September 26, 2019
ORGANIZATION
- Keidanren Calls for English Drug Filings to Be Opened to Japan-Based Firms
September 16, 2026
- JPWA Disbands Kumamoto Quake Disaster Response HQ
September 14, 2026
- BMS Prods Japan to Better Reward Regenerative Medicine Innovation
September 11, 2026
- Prix Galien to Launch Japan Awards in February 2027
September 8, 2026
- FPMAJ Lauds Drug Investment Push, Urges Budget Follow-Through
September 8, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





